An Open-Label, Randomized, Phase II Trial Evaluating the Efficacy and Safety of Standard of Care With or Without Bevacizumab in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Previously Treated With Bevacizumab for Front-Line or Platinum-Sensitive Ovarian Cancer: Rationale, Design, and Methods of the Japanese Gynecologic Oncology Group Study JGOG3023

BMC Cancer - United Kingdom

doi 10.1186/s12885-018-4505-4